PE20130396A1 - N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE DEUTERATED, SALTS AND USES OF THE SAME - Google Patents
N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE DEUTERATED, SALTS AND USES OF THE SAMEInfo
- Publication number
- PE20130396A1 PE20130396A1 PE2013000039A PE2013000039A PE20130396A1 PE 20130396 A1 PE20130396 A1 PE 20130396A1 PE 2013000039 A PE2013000039 A PE 2013000039A PE 2013000039 A PE2013000039 A PE 2013000039A PE 20130396 A1 PE20130396 A1 PE 20130396A1
- Authority
- PE
- Peru
- Prior art keywords
- carboxamide
- chloro
- hydroxy
- phenyl
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
SE REFIERE AL COMPUESTO N-ETIL-N-FENIL-1,2-DIHIDRO-4-HIDROXI-5-CLORO-1-METIL-2-OXOQUINOLIN-3-CARBOXAMIDA (LAQUINIMOD) ENRIQUECIDO CON DEUTERIO DE FORMULA (i), (ii) O (iii) DONDE D ES DEUTERIO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE A) LAQUINIMOD ENRIQUECIDO CON DEUTERIO; B) UN PORTADOR FARMACEUTICAMENTE ACEPTABLE; Y C) EL COMPUESTO 5-CLORO-4-HIDROXI-1-METIL-2-OXO-N-FENIL-1,2-DIHIDROQUINOLIN-3-CARBOXAMIDA O DES-ETIL-LAQUINIMOD EN UNA CANTIDAD MENOR DE 0.1% CON BASE EN EL PESO COMBINADO DE DICHO COMPUESTO Y LAQUINIMOD ENRIQUECIDO CON DEUTERIO. DICHO COMPUESTO SE ADMINISTRA EN UNA CANTIDAD DE 0.2MG A 2MG POR DIA SIENDO UTIL EN EL TRATAMIENTO DE ESCLEROSIS MULTIPLEREFERS TO THE COMPOUND N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLIN-3-CARBOXAMIDE (LAQUINIMOD) ENRICHED WITH DEUTERIUM FORMULA (i), ( ii) OR (iii) WHERE D IS DEUTERIO. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION CONTAINING A) LAQUINIMOD ENRICHED WITH DEUTERIUM; B) A PHARMACEUTICALLY ACCEPTABLE CARRIER; AND C) THE COMPOUND 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLIN-3-CARBOXAMIDE OR DES-ETHYL-LAQUINIMOD IN AN AMOUNT OF LESS THAN 0.1% BASED ON COMBINED WEIGHT OF SAID COMPOUND AND LAQUINIMOD ENRICHED WITH DEUTERIUM. SAID COMPOUND IS ADMINISTERED IN AN AMOUNT OF 0.2MG TO 2MG PER DAY BEING USEFUL IN THE TREATMENT OF MULTIPLE SCLEROSIS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39929710P | 2010-07-09 | 2010-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20130396A1 true PE20130396A1 (en) | 2013-04-19 |
Family
ID=45439026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013000039A PE20130396A1 (en) | 2010-07-09 | 2011-07-08 | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE DEUTERATED, SALTS AND USES OF THE SAME |
Country Status (19)
Country | Link |
---|---|
US (3) | US8580819B2 (en) |
EP (2) | EP3213636A1 (en) |
JP (2) | JP2013535437A (en) |
KR (1) | KR20130092558A (en) |
CN (2) | CN102984939A (en) |
AR (1) | AR082150A1 (en) |
AU (1) | AU2011274496B2 (en) |
BR (1) | BR112013000599A2 (en) |
CA (1) | CA2804986A1 (en) |
CL (1) | CL2013000063A1 (en) |
EA (1) | EA025377B1 (en) |
IL (1) | IL251600A0 (en) |
MX (1) | MX2013000333A (en) |
NZ (1) | NZ606587A (en) |
PE (1) | PE20130396A1 (en) |
SG (2) | SG10201505236YA (en) |
UY (1) | UY33504A (en) |
WO (1) | WO2012006538A1 (en) |
ZA (1) | ZA201300956B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1937642T1 (en) * | 2005-10-19 | 2015-01-30 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
KR20160013273A (en) | 2006-06-12 | 2016-02-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | Stable laquinimod preparations |
SI2234485T1 (en) | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stable laquinimod preparations |
US20100322900A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
CA2769623A1 (en) * | 2009-07-30 | 2011-02-03 | Teva Pharmaceutical Industries Ltd. | Treatment of crohn's disease with laquinimod |
ES2586843T3 (en) | 2009-08-10 | 2016-10-19 | Teva Pharmaceutical Industries Ltd. | Treatment of disorders related to BDNF using laquinimod |
SI2542079T1 (en) * | 2010-03-03 | 2014-08-29 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
NZ602512A (en) * | 2010-03-03 | 2014-07-25 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
MX337614B (en) * | 2010-03-03 | 2016-03-10 | Teva Pharma | Treatment of lupus nephritis using laquinimod. |
EP3213636A1 (en) * | 2010-07-09 | 2017-09-06 | Teva Pharmaceutical Industries, Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
CN106344576A (en) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
JP2015505564A (en) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | Use of laquinimod to treat patients with Crohn's disease who have failed first-line anti-TNEα therapy |
MX2014009889A (en) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-qui noline carboxamide, preparation and uses thereof. |
TW201350467A (en) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide |
TW201400117A (en) | 2012-06-05 | 2014-01-01 | Teva Pharma | Treatment of ocular inflammatory disease using laquinimod |
TW201410244A (en) | 2012-08-13 | 2014-03-16 | Teva Pharma | Laquinimod for treatment of GABA mediated disorders |
JP2015535287A (en) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | Laquinimod amine salt |
CN103848785B (en) * | 2012-12-04 | 2016-07-13 | 上海医药集团股份有限公司 | One class deuterated 3-cyano quinoline compound, its Pharmaceutical composition, preparation method and its usage |
MX2015010967A (en) | 2013-03-14 | 2015-10-26 | Teva Pharma | Transdermal formulations of laquinimod. |
SG11201506409RA (en) | 2013-03-14 | 2015-09-29 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
CN103145562B (en) * | 2013-03-18 | 2015-06-17 | 黄河三角洲京博化工研究院有限公司 | N-ethyl aniline preparation method |
MX2016013944A (en) | 2014-04-29 | 2017-01-09 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status. |
DK3347006T3 (en) | 2015-03-20 | 2022-10-17 | Gaba Therapeutics Inc | DEUTERATED ANALOGUES OF ETIFOXIN, DERIVATIVES THEREOF AND USES THEREOF |
WO2021038267A1 (en) * | 2019-08-28 | 2021-03-04 | 日産自動車株式会社 | Object recognition method and object recognition device |
US11534434B2 (en) | 2019-11-15 | 2022-12-27 | Karuna Therapeutics, Inc. | Xanomeline derivatives and methods for treating neurological disorders |
WO2021123142A1 (en) * | 2019-12-19 | 2021-06-24 | Active Biotech Ab | Compounds for treatment of eye diseases associated with excessive vascularisation |
GB202006390D0 (en) * | 2020-04-30 | 2020-06-17 | Aqilion Ab | Novel treatments |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
SE9801474D0 (en) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
SE9802549D0 (en) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
SE9802550D0 (en) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
TR200103527T2 (en) | 1999-06-07 | 2002-04-22 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New method of preparation and administration containing an acid-labile active compound |
SE0201778D0 (en) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (en) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
SI1937642T1 (en) | 2005-10-19 | 2015-01-30 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
KR20160013273A (en) | 2006-06-12 | 2016-02-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | Stable laquinimod preparations |
KR20100105802A (en) | 2007-04-19 | 2010-09-29 | 콘서트 파마슈티컬즈, 인크. | Deuterated morpholinyl compounds |
SI2234485T1 (en) | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stable laquinimod preparations |
CA2736091A1 (en) * | 2008-09-03 | 2010-03-11 | Teva Pharmaceutical Industries Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
JP2011001308A (en) * | 2009-06-19 | 2011-01-06 | Research Foundation Itsuu Laboratory | Deuterated carbostyril compound |
US20100322900A1 (en) | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
CA2769623A1 (en) | 2009-07-30 | 2011-02-03 | Teva Pharmaceutical Industries Ltd. | Treatment of crohn's disease with laquinimod |
ES2586843T3 (en) | 2009-08-10 | 2016-10-19 | Teva Pharmaceutical Industries Ltd. | Treatment of disorders related to BDNF using laquinimod |
NZ602512A (en) | 2010-03-03 | 2014-07-25 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
MX337614B (en) | 2010-03-03 | 2016-03-10 | Teva Pharma | Treatment of lupus nephritis using laquinimod. |
SI2542079T1 (en) | 2010-03-03 | 2014-08-29 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
EP3213636A1 (en) | 2010-07-09 | 2017-09-06 | Teva Pharmaceutical Industries, Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
KR20130041193A (en) | 2010-07-09 | 2013-04-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
PE20140872A1 (en) | 2010-12-07 | 2014-08-09 | Teva Pharma | USE OF LAQUINIMOD TO REDUCE FATIGUE, IMPROVE FUNCTIONAL STATUS AND IMPROVE QUALITY OF LIFE IN PATIENTS WITH MULTIPLE SCLEROSIS |
-
2011
- 2011-07-08 EP EP16196628.8A patent/EP3213636A1/en not_active Withdrawn
- 2011-07-08 SG SG10201505236YA patent/SG10201505236YA/en unknown
- 2011-07-08 EP EP20110804411 patent/EP2597954A4/en not_active Withdrawn
- 2011-07-08 SG SG2013000948A patent/SG186948A1/en unknown
- 2011-07-08 MX MX2013000333A patent/MX2013000333A/en unknown
- 2011-07-08 JP JP2013519724A patent/JP2013535437A/en not_active Withdrawn
- 2011-07-08 WO PCT/US2011/043383 patent/WO2012006538A1/en active Application Filing
- 2011-07-08 BR BR112013000599A patent/BR112013000599A2/en not_active IP Right Cessation
- 2011-07-08 AR ARP110102478A patent/AR082150A1/en unknown
- 2011-07-08 KR KR1020137003480A patent/KR20130092558A/en not_active Application Discontinuation
- 2011-07-08 CA CA2804986A patent/CA2804986A1/en not_active Abandoned
- 2011-07-08 CN CN2011800340883A patent/CN102984939A/en active Pending
- 2011-07-08 AU AU2011274496A patent/AU2011274496B2/en not_active Ceased
- 2011-07-08 NZ NZ60658711A patent/NZ606587A/en not_active IP Right Cessation
- 2011-07-08 CN CN201410831557.XA patent/CN104610144A/en active Pending
- 2011-07-08 US US13/178,842 patent/US8580819B2/en not_active Expired - Fee Related
- 2011-07-08 PE PE2013000039A patent/PE20130396A1/en not_active Application Discontinuation
- 2011-07-08 EA EA201390081A patent/EA025377B1/en not_active IP Right Cessation
- 2011-07-11 UY UY0001033504A patent/UY33504A/en not_active Application Discontinuation
-
2013
- 2013-01-08 CL CL2013000063A patent/CL2013000063A1/en unknown
- 2013-02-05 ZA ZA2013/00956A patent/ZA201300956B/en unknown
- 2013-10-24 US US14/062,685 patent/US20140051723A1/en not_active Abandoned
-
2014
- 2014-03-14 US US14/213,279 patent/US9102620B2/en not_active Expired - Fee Related
-
2016
- 2016-07-28 JP JP2016148514A patent/JP2017014238A/en active Pending
-
2017
- 2017-04-05 IL IL251600A patent/IL251600A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3213636A1 (en) | 2017-09-06 |
CL2013000063A1 (en) | 2013-05-03 |
US20120010238A1 (en) | 2012-01-12 |
JP2017014238A (en) | 2017-01-19 |
EP2597954A1 (en) | 2013-06-05 |
AR082150A1 (en) | 2012-11-14 |
WO2012006538A1 (en) | 2012-01-12 |
ZA201300956B (en) | 2014-04-30 |
MX2013000333A (en) | 2013-02-26 |
US9102620B2 (en) | 2015-08-11 |
NZ606587A (en) | 2015-03-27 |
EA025377B1 (en) | 2016-12-30 |
SG10201505236YA (en) | 2015-08-28 |
JP2013535437A (en) | 2013-09-12 |
AU2011274496B2 (en) | 2016-03-10 |
BR112013000599A2 (en) | 2016-07-05 |
SG186948A1 (en) | 2013-02-28 |
WO2012006538A8 (en) | 2013-05-23 |
US20140051723A1 (en) | 2014-02-20 |
AU2011274496A1 (en) | 2013-02-28 |
UY33504A (en) | 2012-02-29 |
US20140343096A1 (en) | 2014-11-20 |
EP2597954A4 (en) | 2014-01-01 |
KR20130092558A (en) | 2013-08-20 |
EA201390081A1 (en) | 2013-07-30 |
IL251600A0 (en) | 2017-06-29 |
CN104610144A (en) | 2015-05-13 |
US8580819B2 (en) | 2013-11-12 |
CA2804986A1 (en) | 2012-01-12 |
CN102984939A (en) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20130396A1 (en) | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE DEUTERATED, SALTS AND USES OF THE SAME | |
AR072261A1 (en) | PIPERAZIN-PIRAZOLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME AS ANTICANCERIGEN AGENTS. | |
EA201690102A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE | |
MA34727B1 (en) | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | |
BRPI0407810A (en) | compound, pharmaceutical composition, glucokinase activator, and medicament | |
AR071187A1 (en) | ARILMETIL-THIAZINAMINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
BR112015001839A2 (en) | deuterated ibrutinib | |
EA200701176A1 (en) | NEW NAPHTHALINE COMPOUNDS, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
NZ743714A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
ES2531009T3 (en) | Dicetopiperazine substituted analogs for use as agents for drug administration | |
MX2013002453A (en) | Deuterated analogs of pridopidine useful as dopaminergic stabilizers. | |
AR084349A1 (en) | FUSIONATED DIHIDRO-PIRANO DERIVATIVES AS MODULATORS OF GPR119 | |
MX354102B (en) | Benzimidazole-proline derivatives. | |
BRPI0818893B8 (en) | tropane compounds, their pharmaceutical compositions, their uses and in vitro method of inhibiting hsp90 in a cell | |
BRPI1013821A8 (en) | substituted pyridines as ccr3 antagonists. | |
PA8852101A1 (en) | URACIL CYCLOPROPYLL NUCLEOTIDES | |
MA37886B1 (en) | New bicyclic pyridinones | |
BR112014006248A2 (en) | triazolopyridine compounds as pde10a inhibitors | |
NZ718514A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
JP2012517449A5 (en) | ||
TN2009000483A1 (en) | 7-ALKYNYL-1-8-NAPHTHYRIDONES DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | |
TR201902057T4 (en) | Tetracycline compounds. | |
PH12015502429A1 (en) | Dicarboxylic acid compound | |
GEP20125548B (en) | New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them | |
EA201590051A1 (en) | A NEW CONNECTION, HAVING THE ABILITY TO INHIBIT ENVIRONMENTAL APPLICATICS OF THE APPLICATORIALS-OR, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, A METHOD OF ITS RECEIVING AND A PHARMACEUTICAL COMPOSITION, CONTAINING A COMPOSITION, A PHARMACEUTICAL COMPOSITION, CONTAINMENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |